Stage
No active trials
Next date
None yet
Trials
0 active
4 in total · 3 in the EU
Targets
—
None known yet
What this is
- How it works
- Helps the body keep more of its own GLP-1, a gut hormone, to lower blood sugar.-gliptin: DPP-IV inhibitors WHO name stem
- Tested for
- Type 2 Diabetes
- Main trialPhase 4
- “The aim of this study is to perform a comparison of the efficacy and safety of empagliflozin and vildagliptin in patients with Type 2 Diabetes Mellitus open labelled, multi-centric, parallel, randomized control trial In Type 2 Diabetes patients, impact of empagliflozin (10 mg once or twice daily) versus vildagliptin (50 mg once or twice daily) assessed for Efficacy \& safety parameters to be measured at both the baseline and 24-week visits.”In the company’s words, NCT05359432 on ClinicalTrials.gov
Other drugs for Type 2 Diabetes
- BR1019Boryung Pharmaceutical Co., Ltd · Phase 3
- CagriSemaNovo Nordisk · Phase 3
- QLG1091Qilu Pharmaceutical · Phase 3
- SHR-3167Hengrui · Phase 3
- Maridebart cafraglutideAmgen · Phase 3
- LenbelintideAstraZeneca · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Completed | 10 Aug 2021 | Comparison of Empaglifozin and Vildagliptin in Type 2 Diabetes Mellitus | |
| Phase 2Ended | not given | Study to evaluate the effect of metformin in the prevention of hyperglycemia in HR[+]/HER2[–] PIK3CA-mutated advanced breast cancer patients treated with alpelisib plus endocrine therapy. The Metallica study. | |
| Phase 3Ended | not given | PRODIG : Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early post-transplant period | |
| Phase 4Ended | not given | Open-label, double-arm, controlled, randomized, multicentre clinical trial to evaluate the impact of pharmacogenetic-guided treatment in patients with insufficiently controlled type 2 diabetes |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026